ATE523198T1 - Pyrroloä2,3-düpyrimidine zur behandlung von krebs durch mitosehemmung - Google Patents

Pyrroloä2,3-düpyrimidine zur behandlung von krebs durch mitosehemmung

Info

Publication number
ATE523198T1
ATE523198T1 AT06733825T AT06733825T ATE523198T1 AT E523198 T1 ATE523198 T1 AT E523198T1 AT 06733825 T AT06733825 T AT 06733825T AT 06733825 T AT06733825 T AT 06733825T AT E523198 T1 ATE523198 T1 AT E523198T1
Authority
AT
Austria
Prior art keywords
group
cancer
substituted
heteroalkyl
groups
Prior art date
Application number
AT06733825T
Other languages
English (en)
Inventor
Aleem Gangjee
Original Assignee
Univ Holy Ghost Duquesne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Holy Ghost Duquesne filed Critical Univ Holy Ghost Duquesne
Application granted granted Critical
Publication of ATE523198T1 publication Critical patent/ATE523198T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06733825T 2005-02-10 2006-01-23 Pyrroloä2,3-düpyrimidine zur behandlung von krebs durch mitosehemmung ATE523198T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/055,732 US8030319B2 (en) 2005-02-10 2005-02-10 Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2 3-d]pyrimidines
PCT/US2006/002379 WO2006086144A2 (en) 2005-02-10 2006-01-23 Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines

Publications (1)

Publication Number Publication Date
ATE523198T1 true ATE523198T1 (de) 2011-09-15

Family

ID=36780720

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06733825T ATE523198T1 (de) 2005-02-10 2006-01-23 Pyrroloä2,3-düpyrimidine zur behandlung von krebs durch mitosehemmung

Country Status (7)

Country Link
US (2) US8030319B2 (de)
EP (2) EP1850851B1 (de)
JP (1) JP5192240B2 (de)
KR (1) KR20070119630A (de)
AT (1) ATE523198T1 (de)
AU (1) AU2006213033B2 (de)
WO (1) WO2006086144A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946239B2 (en) * 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
US8252804B2 (en) 2008-10-01 2012-08-28 Duquesne University Of The Holy Spirit Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same
US20110082158A1 (en) * 2008-10-01 2011-04-07 Aleem Gangjee Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP4007368A1 (de) 2016-06-23 2022-06-01 Nokia Technologies Oy Strahlenwechsel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017478A1 (en) 1991-04-08 1992-10-15 Duquesne University Of The Holy Ghost 5-ALKYL-6-[[AMINO]METHYL]PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF PREPARING AND USING THESE DERIVATIVES
US5346900A (en) 1991-04-08 1994-09-13 Duquesne University Of The Holy Ghost 5-alkyl-6-[[amino]methyl]pyrido[2,3-D]pyrimidine derivatives and methods of using these derivatives
US5508281A (en) 1991-04-08 1996-04-16 Duquesne University Of The Holy Ghost Derivatives of pyrido [2,3-d] and [3,2-d] pyrimidine and methods of using these derivatives
US5877178A (en) 1991-04-08 1999-03-02 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5939420A (en) 1991-04-08 1999-08-17 Duquesne University Of The Holy Ghost Pyrrolo 2,3d!derivatives
US5196424A (en) 1992-03-24 1993-03-23 Eli Lilly And Company N-[2-amino-4-substituted[[(pyrrollo or pyrido)[2,3-d]pyrimidinyl]-alkyl]benzoyl]-L-glutamic acids
US6962920B2 (en) 1992-09-23 2005-11-08 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
US6423720B1 (en) 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
US6770652B2 (en) 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same

Also Published As

Publication number Publication date
AU2006213033A1 (en) 2006-08-17
KR20070119630A (ko) 2007-12-20
EP2311461A1 (de) 2011-04-20
EP1850851A4 (de) 2008-09-17
EP1850851A2 (de) 2007-11-07
EP1850851B1 (de) 2011-09-07
JP5192240B2 (ja) 2013-05-08
US8030319B2 (en) 2011-10-04
US8501752B2 (en) 2013-08-06
US20060178380A1 (en) 2006-08-10
AU2006213033B2 (en) 2012-02-16
JP2008530089A (ja) 2008-08-07
WO2006086144A3 (en) 2006-10-26
US20120058203A1 (en) 2012-03-08
WO2006086144A2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
TW200621230A (en) Anti-tumor compounds
TW200604558A (en) (Meth)acrylamide monomers containing hydroxy and silicone functionalities
ATE523198T1 (de) Pyrroloä2,3-düpyrimidine zur behandlung von krebs durch mitosehemmung
TW200633991A (en) Chemical compounds
ATE541959T1 (de) Verfahren zum herstellen von dielektrischen filmen mit hohem k-wert auf basis neuer zirkon und hafnium vorläufer und ihre verwendung zur halbleiterherstellung
NO20084701L (no) Ny heterocyklisk forbindelse eller salt eller intermediat derav
WO2006001967A3 (en) Migrastatin analogs in the treatment of cancer
EA200000327A2 (ru) Новые соединения аминотриазола, способ их получения и содержащие их фармацевтические композиции
ATE556105T1 (de) Substituierte organopolysiloxane und ihre verwendung
BRPI0607772A2 (pt) emprego de polissilazanas como revestimento permanente antiimpressão digital (anti-fingerprint)
GB2546643A (en) Chromatographic materail and method for preparation thereof
WO2007062790A3 (en) Transition metal compound, ligand system, catalyst system and process for preparing polyolefins
MXPA05009437A (es) Sistema apropiado como catalizador para la hidrocianuracion de compuestos olefinicamente insaturados.
DE602004009943D1 (de) 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung
EA201390323A1 (ru) Производные 4-(метиламинофенокси)пиридин-3-илбензамида для лечения рака
TW200619242A (en) Silyl polymers
DK1598358T3 (da) Forbindelser indeholdende 3,4-methylendioxythiophen-enheder
TW200613299A (en) Squarylium compound and color filter containing the same for electronic display device
DE60230817D1 (de) Liganden für asymmetrische reaktionen
SA515360302B1 (ar) مركبات رباعي أكسا ثنائي فوسفا سبيرو
DE602004026110D1 (de) Verfahren zur inhibierung der verfärbung von methylenbisanilinverbindungen
EA200100940A1 (ru) Водорастворимые трансплатиновые комплексы, обладающие противораковым действием, способ их получения и способ лечения
ATE390433T1 (de) Phosphor-enthaltende imidazoline und metallkomplexe davon
DE602006008940D1 (de) Verfahren zur synthese von dialkoxyorganoboranen
TH2001001568A (th) สารประกอบเตตระโซลไซเลน,วิธีสำหรับการสังเคราะห์สารประกอบดังกล่าวและการใช้ของสิ่งนี้

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties